Trials / Completed
CompletedNCT03730337
Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors
Open-label, Uncontrolled, Dose-escalation Study of ONO-7475 Given as Monotherapy and Combinations With ONO-4538 in Patients With Advanced or Metastatic Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Ono Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the tolerability and safety of ONO-7475 monotherapy and combinations with ONO-4538 in patients with advanced or metastatic solid tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ONO-7475 | ONO-7475 specified dose on specified days |
| DRUG | ONO-7475 + ONO-4538 | ONO-7475+ONO-4538 specified dose on specified days |
Timeline
- Start date
- 2018-10-17
- Primary completion
- 2021-06-28
- Completion
- 2022-11-22
- First posted
- 2018-11-05
- Last updated
- 2023-10-04
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT03730337. Inclusion in this directory is not an endorsement.